Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors

Daniel T. Harris, David M Kranz

Research output: Contribution to journalReview article

Abstract

The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.

Original languageEnglish (US)
Pages (from-to)220-230
Number of pages11
JournalTrends in Pharmacological Sciences
Volume37
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Antigen Receptors
T-cells
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
T-Lymphocytes
Tumors
Neoplasms
Antigens
Therapeutics

Keywords

  • CAR
  • TCR
  • cell therapies
  • gene therapies
  • immunotherapy
  • receptors

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Adoptive T Cell Therapies : A Comparison of T Cell Receptors and Chimeric Antigen Receptors. / Harris, Daniel T.; Kranz, David M.

In: Trends in Pharmacological Sciences, Vol. 37, No. 3, 01.03.2016, p. 220-230.

Research output: Contribution to journalReview article

@article{0de384df61dc4cf2ab9ea423d0ccc004,
title = "Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors",
abstract = "The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.",
keywords = "CAR, TCR, cell therapies, gene therapies, immunotherapy, receptors",
author = "Harris, {Daniel T.} and Kranz, {David M}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.tips.2015.11.004",
language = "English (US)",
volume = "37",
pages = "220--230",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Adoptive T Cell Therapies

T2 - A Comparison of T Cell Receptors and Chimeric Antigen Receptors

AU - Harris, Daniel T.

AU - Kranz, David M

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.

AB - The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.

KW - CAR

KW - TCR

KW - cell therapies

KW - gene therapies

KW - immunotherapy

KW - receptors

UR - http://www.scopus.com/inward/record.url?scp=84958744448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958744448&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2015.11.004

DO - 10.1016/j.tips.2015.11.004

M3 - Review article

VL - 37

SP - 220

EP - 230

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 3

ER -